[go: up one dir, main page]

WO2000010552A3 - Use of anti-angiogenic agents for inhibiting vessel wall injury - Google Patents

Use of anti-angiogenic agents for inhibiting vessel wall injury Download PDF

Info

Publication number
WO2000010552A3
WO2000010552A3 PCT/US1999/019218 US9919218W WO0010552A3 WO 2000010552 A3 WO2000010552 A3 WO 2000010552A3 US 9919218 W US9919218 W US 9919218W WO 0010552 A3 WO0010552 A3 WO 0010552A3
Authority
WO
WIPO (PCT)
Prior art keywords
angiogenic agents
vessel wall
neointima
wall injury
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1999/019218
Other languages
French (fr)
Other versions
WO2000010552A2 (en
Inventor
Charles L Brown Iii
Steve Gorlin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Global Vascular Concepts Inc
Original Assignee
Global Vascular Concepts Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Global Vascular Concepts Inc filed Critical Global Vascular Concepts Inc
Priority to AU56871/99A priority Critical patent/AU5687199A/en
Publication of WO2000010552A2 publication Critical patent/WO2000010552A2/en
Publication of WO2000010552A3 publication Critical patent/WO2000010552A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Media Introduction/Drainage Providing Device (AREA)
  • Materials For Medical Uses (AREA)
  • Prostheses (AREA)

Abstract

Use of anti-angiogenic agents to inhibit an undesireable response to vessel wall injury, including stent neointima, dialysis graft neointima, vascular graft induced neointima, and the treatment of benign hypertrophic scar formation as well as the treatment and passivation of unstable atherosclerotic plaques are provided. The invention provides for the use of catheter-based devices for enhancing the local delivery of anti-angiogenic agents into the endothelial tissues of blood vessels of the living body.
PCT/US1999/019218 1998-08-24 1999-08-24 Use of anti-angiogenic agents for inhibiting vessel wall injury Ceased WO2000010552A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU56871/99A AU5687199A (en) 1998-08-24 1999-08-24 Use of anti-angiogenic agents for inhibiting vessel wall injury

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9757998P 1998-08-24 1998-08-24
US60/097,579 1998-08-24

Publications (2)

Publication Number Publication Date
WO2000010552A2 WO2000010552A2 (en) 2000-03-02
WO2000010552A3 true WO2000010552A3 (en) 2000-11-23

Family

ID=22264134

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/019218 Ceased WO2000010552A2 (en) 1998-08-24 1999-08-24 Use of anti-angiogenic agents for inhibiting vessel wall injury

Country Status (2)

Country Link
AU (1) AU5687199A (en)
WO (1) WO2000010552A2 (en)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6908910B2 (en) 1993-08-06 2005-06-21 The Children's Medical Center Corporation Estrogenic compounds as anti-mitotic agents
US5504074A (en) 1993-08-06 1996-04-02 Children's Medical Center Corporation Estrogenic compounds as anti-angiogenic agents
US7772220B2 (en) * 2004-10-15 2010-08-10 Seo Hong Yoo Methods and compositions for reducing toxicity of a pharmaceutical compound
CA2348835A1 (en) 1998-10-28 2000-05-04 Cornell Research Foundation, Inc. Methods for regulating angiogenesis and vascular integrity using trk receptor ligands
US7087592B1 (en) 1999-08-23 2006-08-08 Entre Med, Inc. Compositions comprising purified 2-methoxyestradiol and methods of producing same
EP1214077B1 (en) * 1999-09-21 2004-01-28 Institut de Cardiologie de Montreal Local delivery of 17-beta estradiol for improving vascular endothelium function after vascular injury
WO2001034132A2 (en) * 1999-11-09 2001-05-17 Pharmacia Corporation Use of an aldosterone antagonist for treating restenosis
DE19957342A1 (en) * 1999-11-29 2001-05-31 Gruenenthal Gmbh Treatment of interleukin (IL)-12 mediated illnesses comprises simultaneous administration of thalidomide or analogue and antiinflammatory cytokine
US7182953B2 (en) * 1999-12-15 2007-02-27 Celgene Corporation Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders
JP2004518611A (en) * 2000-07-27 2004-06-24 ファルマシア・コーポレーション Aldosterone blocker therapy to prevent or treat inflammation-related disorders
US6716829B2 (en) 2000-07-27 2004-04-06 Pharmacia Corporation Aldosterone antagonist and cyclooxygenase-2 inhibitor combination therapy to prevent or treat inflammation-related cardiovascular disorders
US7135581B2 (en) 2000-08-18 2006-11-14 Entremed, Inc. Antiangiogenic agents
US6995278B2 (en) 2000-08-18 2006-02-07 Entre Med, Inc. Antiangiogenic agents
US6436629B1 (en) * 2000-10-27 2002-08-20 The Regents Of The University Of California Modulating angiogenesis
WO2002042319A2 (en) * 2000-11-27 2002-05-30 Entremed, Inc. 2-substituted estrogens as antiangiogenic agents
US7084117B2 (en) * 2001-01-12 2006-08-01 Societe De Conseils De Recherches Et D'applications Scientifiques, Sas Pharmaceutical compositions which inhibit vascular proliferation and method of use thereof
DE10115740A1 (en) 2001-03-26 2002-10-02 Ulrich Speck Preparation for restenosis prophylaxis
US6625486B2 (en) 2001-04-11 2003-09-23 Advanced Cardiovascular Systems, Inc. Method and apparatus for intracellular delivery of an agent
AU4239302A (en) * 2001-06-28 2003-01-02 Pfizer Products Inc. Benzoic acid substituted benzopyrans for the treatment of atherosclerosis
CN1625412A (en) * 2002-01-30 2005-06-08 法玛西雅公司 Combination therapy of aldosterone antagonists and non-steroidal anti-inflammatory agents for the prevention or treatment of cardiovascular diseases
AU2003227454B2 (en) * 2002-04-22 2009-07-30 Research Foundation Itsuu Laboratory Medicament for therapeutic treatment of vascular disease
EP1539268A1 (en) * 2002-09-12 2005-06-15 Estrogen Vascular Technology, LLC Apparatus and method for delivering compounds to a living organism
DE10244847A1 (en) 2002-09-20 2004-04-01 Ulrich Prof. Dr. Speck Medical device for drug delivery
EP1633367A2 (en) 2003-05-28 2006-03-15 EntreMed, Inc. Antiangiogenic agents
US20070110785A1 (en) * 2003-07-03 2007-05-17 Eugene Tedeschi Medical devices with proteasome inhibitors for the treatment of restenosis
WO2005061448A1 (en) * 2003-12-24 2005-07-07 Monash University Compositions and methods for treating vascular conditions
US7498322B2 (en) 2004-03-12 2009-03-03 Entremed, Inc. Antiangiogenic agents
WO2006034345A2 (en) 2004-09-20 2006-03-30 Research Development Foundation Avicin-coated stents
MX2007006601A (en) * 2004-12-02 2007-06-19 Abbott Lab Methods for reducing intimal hyperplasia, smooth muscle cell proliferation and restenosis in mammals.
US7286295B1 (en) 2005-11-30 2007-10-23 Sandia Corporation Microoptical compound lens
CA2646065C (en) 2006-03-20 2014-01-14 Entremed, Inc. Disease modifying anti-arthritic activity of 2-methoxyestradiol
EP2356998A1 (en) * 2010-02-17 2011-08-17 Université de Liège A pharmaceutical composition for treatment of thrombosis-related diseases comprising a fragment of prolactin (PRL)-growth hormone (GH) - placental lactogen (PL)-family protein
WO2011119536A1 (en) 2010-03-22 2011-09-29 Abbott Cardiovascular Systems Inc. Stent delivery system having a fibrous matrix covering with improved stent retention
CN113332298A (en) * 2021-05-27 2021-09-03 成都医学院 New use of minocycline as a tyrosine kinase inhibitor
DE102024104754B4 (en) 2024-02-21 2026-01-08 Acandis Gmbh Medical device with improved antithrombotic effect

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991019731A1 (en) * 1990-06-11 1991-12-26 The Upjohn Company Steroids which inhibit angiogenesis
US5096892A (en) * 1988-05-27 1992-03-17 The Children's Medical Center Corporation Arylsulfatase inhibition and potentiation of angiostatic steroids and heparin
WO1992015286A1 (en) * 1991-02-27 1992-09-17 Nova Pharmaceutical Corporation Anti-infective and anti-inflammatory releasing systems for medical devices
US5286254A (en) * 1990-06-15 1994-02-15 Cortrak Medical, Inc. Drug delivery apparatus and method
WO1994026888A1 (en) * 1993-05-19 1994-11-24 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of proliferation of vascular smooth muscle cell
WO1995003036A1 (en) * 1993-07-19 1995-02-02 Angiogenesis Technologies, Inc. Anti-angiogenic compositions and methods of use
WO1995005866A1 (en) * 1993-08-27 1995-03-02 Cortrak Medical Inc. Simultaneous angioplasty and drug delivery
WO1997016197A1 (en) * 1995-10-30 1997-05-09 Les Laboratoires Aeterna Inc. Extracts of shark cartilage
WO1998030255A2 (en) * 1997-01-09 1998-07-16 Localmed, Inc. Localized intravascular delivery of antioxidant substances for inhibition of restenosis in recanalized blood vessels
US5788979A (en) * 1994-07-22 1998-08-04 Inflow Dynamics Inc. Biodegradable coating with inhibitory properties for application to biocompatible materials
WO1999009982A1 (en) * 1997-08-25 1999-03-04 Harold Brem Prevention of adhesions and excessive scar formation using angiogenesis inhibitors

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5096892A (en) * 1988-05-27 1992-03-17 The Children's Medical Center Corporation Arylsulfatase inhibition and potentiation of angiostatic steroids and heparin
WO1991019731A1 (en) * 1990-06-11 1991-12-26 The Upjohn Company Steroids which inhibit angiogenesis
US5286254A (en) * 1990-06-15 1994-02-15 Cortrak Medical, Inc. Drug delivery apparatus and method
WO1992015286A1 (en) * 1991-02-27 1992-09-17 Nova Pharmaceutical Corporation Anti-infective and anti-inflammatory releasing systems for medical devices
WO1994026888A1 (en) * 1993-05-19 1994-11-24 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of proliferation of vascular smooth muscle cell
WO1995003036A1 (en) * 1993-07-19 1995-02-02 Angiogenesis Technologies, Inc. Anti-angiogenic compositions and methods of use
WO1995005866A1 (en) * 1993-08-27 1995-03-02 Cortrak Medical Inc. Simultaneous angioplasty and drug delivery
US5788979A (en) * 1994-07-22 1998-08-04 Inflow Dynamics Inc. Biodegradable coating with inhibitory properties for application to biocompatible materials
WO1997016197A1 (en) * 1995-10-30 1997-05-09 Les Laboratoires Aeterna Inc. Extracts of shark cartilage
WO1998030255A2 (en) * 1997-01-09 1998-07-16 Localmed, Inc. Localized intravascular delivery of antioxidant substances for inhibition of restenosis in recanalized blood vessels
WO1999009982A1 (en) * 1997-08-25 1999-03-04 Harold Brem Prevention of adhesions and excessive scar formation using angiogenesis inhibitors

Also Published As

Publication number Publication date
WO2000010552A2 (en) 2000-03-02
AU5687199A (en) 2000-03-14

Similar Documents

Publication Publication Date Title
WO2000010552A3 (en) Use of anti-angiogenic agents for inhibiting vessel wall injury
WO2000013702A3 (en) Use of an angiogenic factor for the treatment of microvascular angiopathies
EP1616563A3 (en) Perivascular administration of anti-angiogenic factors for treating or preventing vascular diseases
AU1676999A (en) Ultrasonography of the prostate
WO2001097850A3 (en) Combinations and compositions which interfere with vegf/vegf and angiopoietin/tie receptor function and their use (ii)
AU2002251898A1 (en) Guidewire and lock mechanism
DK0964646T3 (en) Surgical pelvis
NO20021281D0 (en) Wash off investment composition
WO2000038665A3 (en) Use of an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
CA2385997A1 (en) Surgical retractor
WO2003028802A3 (en) Devices for treating atrial fibrilation
WO2002000210A3 (en) Use of agents capable of reducing uric acid levels for the treatment of cardiovascular disease
WO2007105210A3 (en) Therapeutic uses of cannabidiol compounds
WO2004031129A3 (en) Compounds for use in the treatment of autoimmune diseases, immuno-allergical diseases and organ or tissue transplantation rejection
WO2002030889A3 (en) A method for inhibiting new tissue growth in blood vessels in a patient subjected to blood vessel injury
WO2002011747A3 (en) Transglutaminase for inhibiting angiogenesis
EP0363671A3 (en) Use of ace inhibitors against the formation of neo-intima after vascular infliction
EP1417971A3 (en) Use of an angiogenic factor for the treatment of microvascular angiopathies
PL354961A1 (en) Prevention and treatment of diseases associated with blood coagulation
WO2003059192A3 (en) C3 exoenzyme-coated stents and uses thereof for treating and preventing restenosis
TR200501763T2 (en) Treatment and screening methods
WO2004045531A3 (en) Protection of cardiac myocardium
WO1998030255A3 (en) Localized intravascular delivery of antioxidant substances for inhibition of restenosis in recanalized blood vessels
WO2001056593A3 (en) Use of vascular endothelial growth factor, placenta growth factor or both for preventing or treating ischemic diseases or stroke
GB9904976D0 (en) Intravenous coagulation catheter for treatment of varicose veins

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase